Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.49 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 7/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294478 | 0.93 | NPC1 (0.48) | MAPTKMT2AMEN1TP53RAB9A | |
| SCHEMBL2296419 | 0.92 | NPC1 (0.49) | MAPTSAE1UBA2KMT2AMEN1 | |
| SCHEMBL2299812 | 0.91 | NPC1 (0.45) | MAPTKMT2AMEN1TP53RAB9A | |
| SCHEMBL2299394 | 0.91 | F2 (0.44) | MAPTKMT2AMEN1TP53RAB9A | |
| SCHEMBL2298655 | 0.90 | RAB9A (0.48) | MAPTTP53RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL2296047 | 0.90 | NPC1 (0.42) | MAPTKMT2AMEN1TP53RAB9A | |
| SCHEMBL2292564 | 0.90 | NPC1 (0.51) | MAPTKMT2AMEN1TP53RAB9A | |
| SCHEMBL2297422 | 0.90 | KMT2A (0.46) | MAPTKMT2AMEN1TP53RAB9A | |
| SCHEMBL2295384 | 0.89 | KCNK3 (0.46) | MAPTKMT2AMEN1TP53RAB9A | |
| SCHEMBL5282260 | 0.89 | MEN1 (0.48) | MAPTKMT2AMEN1TP53RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003806-B2 | Integrin antagonists useful as anticancer agents | OSI Pharmaceuticals, LLC (US) | 2011-08-23 | — | — | US | claimed |
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ALCATEL LUCENT (FR) | 2006-06-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116383-A1 | Integrin antagonists useful as anticancer agents | ITGB5, ITGA5, ITGB1 | MAPT 4745/4885SAE1 3161/4885UBA2 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.